Enabling IntraBiotics Pharmaceuticals Inc. to ramp up its clinical programs for iseganan, the company raised $39 million gross in a public stock offering Wednesday. (BioWorld Today)

Cytokinetics Inc. priced its initial public offering Thursday, raising $89.7 million, slightly more than it expected to raise when it filed in January. (BioWorld Today)